Chinese manufacturers increase exports to non-U.S. markets; Revisions to the Anti-Unfair Competition Law address challenges to fair competition; China's data centers in Tibet aim to power much of China's AI
U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model
CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
Chinese exporters ship goods through third countries to conceal true origin; China’s stringent cross-border data transfer rules force European pause in funding of scientific research; and Draft revisions of arbitration law aim to increase oversight and international cooperation on arbitration cases
Beijing IP Court issues first ruling on protecting AI model parameters; Chinese pharma companies are using “NewCo” strategy to expand overseas; and China reduces entry restrictions for select industries.
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
